All Updates

All Updates

icon
Filter
Partnerships
Aranscia and Signature RX partner to optimize GLP-1 treatments with personalized medication management
Precision Medicine
Jun 20, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 20, 2024

Aranscia and Signature RX partner to optimize GLP-1 treatments with personalized medication management

Partnerships

  • Aranscia and Signature RX have partnered for the development of new biomarkers and personalized medication management solutions relating to GLP-1 treatments. GLP-1s are a class of medications indicated for chronic diseases like type 2 diabetes and obesity.

  • This partnership aims to expand the exploration of the pharmacogenomic parameters in GLP-1 receptor agonists, allowing more individualized and effective medication management and catering to the supply chain requirements of such medications. With the help of AccessDx Laboratory, an Aranscia subsidiary dedicated to developing new companion diagnostics for GLP-1 medications, and YouScript, a pharmacogenomics platform, a personalized program will be implemented to improve patient outcomes and reduce care costs. 

  • Aranscia specializes in diagnostic software and services that enhance precision medicine. The company’s portfolio includes solutions such as YouScript and 2bPrecise, a software suite that integrates genomic data into electronic medical records (EMRs) to assist healthcare providers in making informed decisions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.